Zobrazeno 1 - 2
of 2
pro vyhledávání: '"621"'
Autor:
Takafumi Sangai, Thomas Yau, Yen-Shen Lu, Kun Ming Rau, Ting Ying Ng, Ming-Shen Dai, Roger K.C. Ngan, Johnson Lin, Ming-Feng Hou, Sung-Bae Kim, Peter Ang, Ava Kwong, Mei Chieh Chen, Shang Wen Chen, Norikazu Masuda, Richard A. Bryce, Sung Chao Chu, Hyun Cheol Chung, Samuel Ow, Judith Bebchuk, Yin Hsun Feng, Yoon Sim Yap, Keun Seok Lee, Ling Ming Tseng, Victor C. Kok, Shou Tung Chen
Publikováno v:
Breast Cancer Research and Treatment
Purpose Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, has demonstrated systemic efficacy and intracranial activity in various stages of HER2+breast cancer. NALA was a phase III randomized trial that assessed the efficacy and safety of
Autor:
Brian Hutton, Carol Stober, Ricardo Fernandes, Risa Shorr, Dean Fergusson, Lisa Vandermeer, Shaan Dudani, Mark Clemons, Mohamed F.K. Ibrahim, Kirstin Perdrizet, Sasha Mazzarello, Habeeb Majeed
Publikováno v:
Breast Cancer Research and Treatment. 161:1-10
Due to the high rate of febrile neutropenia (FN) with docetaxel-cyclophosphamide (DC) chemotherapy, primary FN prophylaxis is recommended. However, the optimal choice of prophylaxis [i.e., granulocyte-colony stimulating factors (G-CSF) or antibiotics